ACURX PHARMACEUTICALS, INC.

Analyst Reco. Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
2.19 ^USD	+5.80%		+10.61%	-42.82%

Apr. 04	Top Premarket Gainers	MT
Mar. 19	H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	Mar. 19	MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $14 From $13, Keeps Buy Rating	Dec. 15	MT
Acurx Reports 96% Clinical Cure Rate in Phase 2 Trial of Ibezapolstat in C. Difficile Infection; Shares Fall	Nov. 02	MT
Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection	Nov. 02	CI
Maxim Raises Price Target on Acurx Pharmaceuticals to $10 From $7, Keeps Buy Rating	23-10-11	MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $13 From $14, Keeps Buy Rating	23-08-15	MT
HC Wainwright Initiates Acurx Pharmaceuticals With Buy Rating, Sets $14 Price Target	22-12-19	MT
Alliance Global Starts Acurx Pharmaceuticals at Buy With $14 Price Target	22-10-20	MT
Maxim Group Starts Acurx Pharmaceuticals at Buy With $12 Price Target	21-11-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer